Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study

IF 0.7 Q4 RESPIRATORY SYSTEM Lung Cancer Management Pub Date : 2019-09-02 DOI:10.2217/lmt-2019-0004

S. Thongprasert, Sarayut Lucien Geater, D. Clement, A. Abdelaziz, J. Reyes-Igama, D. Jovanovic, A. Alexandru, M. Schenker, V. Sriuranpong, P. Serwatowski, S. Suresh, A. Cseh, R. Gaafar

{"title":"Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study","authors":"S. Thongprasert, Sarayut Lucien Geater, D. Clement, A. Abdelaziz, J. Reyes-Igama, D. Jovanovic, A. Alexandru, M. Schenker, V. Sriuranpong, P. Serwatowski, S. Suresh, A. Cseh, R. Gaafar","doi":"10.2217/lmt-2019-0004","DOIUrl":null,"url":null,"abstract":"Aim: The current study evaluated the efficacy and tolerability of second-line afatinib in patients with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC) following chemotherapy. Patients & methods: In this open-label, single-arm Phase IV study, patients with EGFRm+ (Del19/L858R) NSCLC who had progressed following platinum-based chemotherapy received afatinib (starting dose 40 mg/day). The primary end point was confirmed objective response. Results: 60 patients received afatinib for a median duration of 11.5 months. 50% of patients had a confirmed objective response, of median duration 13.8 months. Median progression-free survival was 10.9 months. The most common treatment-related adverse events were diarrhea (72%), rash (28%) and paronychia (23%). Conclusion: Our data support the use of afatinib (40 mg/day) as an effective and well-tolerated second-line treatment in EGFRm+ NSCLC.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2019-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0004","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/lmt-2019-0004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 3

Abstract

Aim: The current study evaluated the efficacy and tolerability of second-line afatinib in patients with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC) following chemotherapy. Patients & methods: In this open-label, single-arm Phase IV study, patients with EGFRm+ (Del19/L858R) NSCLC who had progressed following platinum-based chemotherapy received afatinib (starting dose 40 mg/day). The primary end point was confirmed objective response. Results: 60 patients received afatinib for a median duration of 11.5 months. 50% of patients had a confirmed objective response, of median duration 13.8 months. Median progression-free survival was 10.9 months. The most common treatment-related adverse events were diarrhea (72%), rash (28%) and paronychia (23%). Conclusion: Our data support the use of afatinib (40 mg/day) as an effective and well-tolerated second-line treatment in EGFRm+ NSCLC.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

阿法替尼治疗化疗后携带常见EGFR突变的局部晚期/转移性NSCLC：一项IV期研究

目的：评价二线阿法替尼治疗化疗后EGFR突变阳性（EGFRm+）非小细胞肺癌（NSCLC）患者的疗效和耐受性。患者和方法：在这项开放标签的单臂IV期研究中，在铂类化疗后进展的EGFRm+（Del19/L858R）NSCLC患者接受了阿法替尼（起始剂量40 mg/天）治疗。主要终点是确认的客观反应。结果：60名患者接受阿法替尼治疗，中位持续时间11.5个月。50%的患者有明确的客观反应，中位持续时间为13.8个月。中位无进展生存期为10.9个月。最常见的治疗相关不良事件是腹泻（72%）、皮疹（28%）和甲沟炎（23%）。结论：我们的数据支持阿法替尼（40mg/天）作为EGFRm+NSCLC的一种有效且耐受性良好的二线治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Lung Cancer Management RESPIRATORY SYSTEM-

CiteScore

2.30

自引率

0.00%

发文量